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Abstract
Background: Cancer survival is lower in socioeconomically deprived communities, partly due to low awareness of
symptoms, negative beliefs and delayed help-seeking. We developed an interactive health check questionnaire facilitated by
trained lay advisors. It entails 29 questions about background, lifestyle and health with tailored behaviour change advice.
Personalised results are printed using a traffic light (red/amber/green) system, highlighting areas where action should be
taken. This is an individually randomised control trial to test effectiveness of the health check on symptom recognition.
Methods: A total 246 participants aged 40+ years will be recruited from community and healthcare settings in
socioeconomically deprived areas of Yorkshire and South Wales. Participants will be randomised to receive the health check
or standard care (1:1 ratio). Outcome measures include: adapted Awareness and Beliefs about Cancer (primary outcome),
brief State Trait Anxiety Inventory, intentions and motivation to adopt recommended health behaviours (early symptom
presentation, cancer screening and lifestyle behaviours), adapted Client Service Receipt Inventory, brief medical history/
screening and demographic questionnaire at: baseline; 2-weeks; and 6-months post-randomisation. A purposive sample of
intervention sessions will be audio-recorded (n = 24) and half will additionally be observed (n = 12). Semi-structured
interviews will take place at 2-weeks (n = 30) and 6-months (n = 15–20) post-randomisation. The primary analysis will
compare cancer symptom recognition scores between arms at 2-weeks. Secondary analysis will assess cancer beliefs,
barriers/time to presentation, screening and lifestyle behaviours, anxiety and costs. A process evaluation will assess
intervention fidelity, dose and contamination.
The London-Surrey NHS Research Ethics Committee (Ref: 17/LO/1507) approved this trial.
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Discussion: This is a trial of a theoretically underpinned complex intervention which has undergone phase 1 and 2
development work. The findings will evaluate evidence about the effect of the health check on symptom awareness.
Although there are few exclusion criteria there are limitations regarding the population we are able to reach, who may have
even higher risks of late diagnosis and poor cancer prognosis. However, the health check has the potential to improve
cancer symptom awareness and encourage early help-seeking behaviour in deprived populations, thereby reducing
inequalities in longer term cancer outcomes.
Trial Registration: Retrospectively registered with ISRCTN (Ref:ISRCTN16872545) on 12.01.2018.
Keywords: Cancer Awareness, Behaviour Change, Help-seeking, Deprived Communities, Randomised Control Trial
Background
Cancer outcomes are considerably poorer in the most
socioeconomically deprived areas of the UK [1–3], in-
cluding West and South Yorkshire and South Wales.
This reflects high risk lifestyle behaviours (e.g. smok-
ing, poor diet, low exercise) which have been linked
to increased risk of developing cancer [4]. Evidence
suggests that low awareness of cancer symptoms, fear
of cancer or fatalistic beliefs about cancer and con-
cerns over wasting the doctor’s time are higher in
lower socioeconomic groups [5] resulting in delayed
help seeking [5–8], in turn leading to late stage
diagnosis and lower uptake of cancer screening [9].
There is a need for interventions which overcome
this, by addressing negative beliefs about cancer and
highlighting the benefits of early diagnosis, as well as
raising awareness of potential cancer symptoms, in
order to reduce the time to symptom presentation
and improve long term treatment outcomes.
Mass media awareness campaigns have been widely
used across public health with the aim of changing a
range of health behaviours (including increasing cancer
knowledge and symptom recognition and encouraging
help seeking behaviour) [10]. Emerging evidence sug-
gests that targeted, intensive community-based behav-
iour change interventions may be more successful at
improving cancer awareness in high risk disadvantaged
populations [11–15]. In particular, interventions that
draw on pre-existing social networks and social influ-
ences [16] have the potential for more successful out-
comes in this context. Involving trusted and trained lay
advisors may be a successful method for engaging and
delivering cancer messages in a compassionate and
non-judgmental manner to people living in deprived
communities [11, 17]. However, the Improving Rural
Cancer Outcomes (IRCO) trial of a community-based
symptom awareness and GP educational intervention in
rural Western Australia did not observe a significant ef-
fect of the intervention on time to symptom presenta-
tion [18]. The authors suggest that this may reflect
limited intervention “dose”. It is therefore important to
consider the optimal dose and intensity of cancer
awareness interventions targeted at high risk disadvan-
taged populations.
While previous targeted community-based complex
interventions that use evidence-based behaviour change
techniques (BCTs) are promising in encouraging cancer
awareness and earlier help-seeking [12–14], high quality
evidence is needed to test intervention effectiveness in
‘real life’ settings. The ABACus 3 trial is testing a tai-
lored health check intervention facilitated by a lay ad-
visor in deprived communities in South and West
Yorkshire and South Wales.
Health Check intervention
We developed and piloted a community outreach health
check intervention facilitated through a lay advisor, de-
signed to improve cancer symptom knowledge, encour-
age positive beliefs in relation to early cancer detection,
and increase motivation to seek help among adults living
in deprived communities [16, 19]. The health check has
been informed by a theoretical understanding of the bar-
riers and enablers to timely help-seeking among people
living in disadvantaged communities [19–21], and com-
prises an interactive touchscreen questionnaire with be-
havioural support delivered face-to-face by a trained lay
advisor (see Fig. 1 for screenshot of the touch screen
questionnaire). The intervention is primarily designed to
reduce the “patient interval”, defined as the time be-
tween appraising a bodily change as a potential symptom
of cancer and presenting in primary care [7]. It also at-
tempts to integrate early symptom detection with cancer
screening and cancer prevention recommendations, by
including content relating to cancer symptoms, screen-
ing, and risk factors (i.e. smoking, diet and inactivity).
In line with the Medical Research Council guidance
on developing and evaluating complex interventions
[22], two phases of development and feasibility/pilot
testing were undertaken in partnership with local stake-
holder groups. Findings from phase 1 suggested that the
health check is beneficial and acceptable to members of
the public, health professionals and community partners
living and working in deprived areas of South Wales
[19]. Results from phase 2 demonstrated the feasibility
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and acceptability of recruiting people from healthcare
and community settings within disadvantaged communi-
ties to undertake the health check [16].
The health check comprises 29 questions divided into
three main sections; ‘About You’, ‘Your Lifestyle’ and ‘Your
Health’. Questions are tailored according to participants’
age and gender (See Table 1 for a breakdown of the
questions). Individualised results are provided in a ‘Re-
sults’ section and are displayed using a traffic light sys-
tem, with ‘green’ indicating results where no signposting
or change is suggested, ‘amber’ indicating an area where
signposting or change could be considered, and ‘red’ re-
sults indicating that action should be taken. Information
and signposting to relevant services (for example, stop
smoking and weight loss services) are provided by the
lay advisors, based on individual results and tailored to
local availability. The intervention manual details all
written and verbal information to be provided to partici-
pants for each response type across each question. It
also maps out each of the BCTs to be used within each
section. Lay advisors are extensively trained to deliver
the intervention and are formally assessed to ensure fa-
miliarity with all components of the intention (i.e. ‘About
You’, ‘Lifestyle’, ‘Your Health’) and associated BCTs tai-
lored according to individual responses.
Aim and Objectives
The aim of the trial is to evaluate the effectiveness of a
community-based cancer awareness intervention in so-
cioeconomically deprived communities. Specific objec-
tives are to:
1. Test the effects of the health check on cancer
symptom awareness and help-seeking behaviour
among adults living in socioeconomically deprived
communities in South and West Yorkshire and
South-East Wales.
2. Evaluate the costs associated with the health check
and estimate the cost-effectiveness of the
intervention.
3. Assess whether the intervention was delivered as
intended, whether there are any contaminating
factors to understand the mechanisms of change.
Methods
Patient and Public Involvement
The trial team includes two patient/public research part-
ners (one of whom was also involved in the phase 2
study) who provide support and knowledge at every
stage of the research process. One partner lives in one of
the target recruitment areas, the other has significant
family associations with the other area. Both have been
affected by cancer.
The research partners have been critical for the
early development and set-up of the trial and have
provided detailed input to the protocol development.
They additionally contribute to all public facing mate-
rials (i.e. information booklet content and design,
questionnaire design etc.), generate ideas on how best
to engage the target population, support data inter-
pretation as well as provide ideas on dissemination
opportunities.
Fig. 1 Screen shot of the ABACus Health check ‘Your Health’ Section
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Trial design and setting
This is an unblinded individually Randomised Con-
trolled Trial of an online Cancer Health Check interven-
tion with additional tailored verbal information delivered
by a lay advisor in areas of high deprivation in South
and West Yorkshire (i.e. Sheffield, Wakefield, Barnsley,
Doncaster, Rotherham etc.) and South-East Wales (i.e.
Merthyr Tydfil, Newport etc.) UK. See Fig. 2 for a flow
diagram of the trial design.
Areas of high deprivation are identified using the
Index of Multiple Deprivation (IMD) for England [23]
and the Welsh Index of Multiple Deprivation (WIMD)
for Wales [24]. Settings include community (local com-
munity groups, one-to-one community sessions, com-
munity events) and healthcare (GP practices and
community pharmacies) venues.
This protocol has been drafted in accordance with the
SPIRIT guidelines [25].
Participant selection
All participants must meet the following eligibility
criteria.
Inclusion criteria:
 Aged 40 years and over.
 Recruited from socioeconomically deprived areas
(i.e. lowest quintile) of South and West Yorkshire
(i.e. Sheffield, Barnsley, Rotherham, Wakefield) as
measured by the IMD [23] or South-East Wales (i.e.
Merthyr Tydfil and Newport) as measured by the
WIMD [24].
Exclusion criteria:
 Non-English speakers.
 Unable to give written informed consent (as defined
by Good Clinical Practice [26]).
 A participant from the phase 2 study.
Outcomes
The primary outcome is cancer symptom knowledge
[27] including specific (e.g. rectal bleeding, unusual
lump) and non-specific (e.g. tiredness, unexplained
weight loss) symptoms measured at two weeks
post-randomisation.
Secondary outcomes include: cancer beliefs [27]; bar-
riers to presentation [27, 28]; help-seeking intentions
[27]; state anxiety [29]; intervention implementation
costs; cost-effectiveness; intentions and confidence to
adopt recommended health behaviours where relevant
(smoking, physical activity, weight loss, fruit and vege-
table intake, alcohol consumption, screening attendance,
symptom presentation) [4, 30].
Measures
The following measures will be used:
 Adapted Awareness and Beliefs About Cancer
questionnaire (ABC) [27].
Table 1 Interactive Health Check Questions
Sections Questions
Section 1:
About You
Have you ever been diagnosed with cancer?
Do you have 2 or more close relatives who have
been under the age of 50 when diagnosed with
cancer?
Please give your height in Feet and Inches /
Centimetres
Please give your weight in Stones and Pounds/Kilos
Did you receive your bowel screening kit in the
post?
If yes, did you send it back?
Have you been invited for a cervical smear test?
If yes, did you attend?
Have you been invited for your breast screening
test?
If yes, did you attend?
Section 2: Your
Lifestyle
Do you smoke?
If yes, On average How many cigarettes a day do
you smoke
Are you exposed to another person’s smoke on a
regular basis?
Do you drink alcohol?
If yes, on average How many units of Alcohol do
you drink each week?
On average, how many hours a week do you
exercise in total, adding up any daily amounts?
How often do you eat 5 portions of fruit and
vegetables in a day?
Section 3: Your
Health
Do you have a cough that won’t go away?
If yes, do you bring up blood when you cough?
Have you noticed any unusual lumps on your body
(e.g. breasts, testicles, armpits, groin)?
Have you noticed a change in how your skin looks
(e.g. change to a mole, freckle or patch of skin)?
Do you have a sore or ulcer in your mouth that will
not heal?
Have you noticed a change or any blood in your
poo?
Do you have any problems when peeing?
Do you have any unexplained bleeding (e.g. blood
in your pee, bleeding from your bottom, vaginal
bleeding during /after sex or in between periods)?
Do you have difficulty swallowing?
Have you been losing weight without trying to?
Have you noticed any unexplained change in your
appetite?
Do you feel tired most of the time?
Do you have an unexplained pain that won’t go
away?
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(The ABC measure was adapted to be used with this
population during phase 2 and has been further
refined following phase 2 findings. Changes made
mainly focus on phrasing and wording of questions
to ensure they are clearly understood by the target
population.)
 Six-item short-form State-Trait Anxiety Inventory
(STAI-6) [29].
 Client Service Receipt Inventory.
 Behavioural intentions and confidence questionnaire
developed using Theory of Planned Behaviour [30].
Participant Identification & Recruitment
Participants will be identified and recruited by the lay
advisors with support from local site staff and/or local
research nurses/officers where possible. Recruitment
days will be arranged in advance and will take place at
local facilities within communities identified as areas of
high socioeconomic deprivation (using the IMD and
WIMD).
A total of 246 participants will be recruited to the trial,
with two thirds (n = 164) of participants recruited from
South/West Yorkshire and one third (n = 82) recruited
from South-East Wales over a 15 month period. This re-
flects strategic priorities of the funder to address the
needs of the Yorkshire population, while recognising
similarities in the sociodemographic characteristics of
the populations across the two geographical sites.
Venues will provide access to a private room to ensure
participant privacy and confidentiality. Two recruitment
methods will be used: Route 1 - pre-booked appointments,
and Route 2 – opportunistic. Wherever possible,
pre-booked appointments (with support from local staff)
will be used to book in interested individuals. Opportunistic
recruitment will be used where local staff are unable to sup-
port the appointment system. In such instances, lay advi-
sors will either visit venues a few days in advance to
approach individuals and book them in for the upcoming
recruitment day or approach potential recruits on the day
or a combination of both.
Screening, registration and consent
The lay advisors will initially check participant eligibility
verbally when individuals show an interest in the study
and if confirmed as eligible will then proceed to full re-
cruitment. The study will be explained to individuals
with the support of the participant information booklets.
Those individuals who proceed to recruitment will be
asked to provide written informed consent at which
point their eligibility will be formally confirmed (using a
checklist) by the lay advisor. We will additionally seek
consent from participants at recruitment to take part in
the qualitative aspects of the trial (if relevant) and to be
contacted in the future should a related follow-on study
take place.
Randomisation
Participants will be individually randomised to either
intervention (facilitated health check) or control
(usual available care/support) in a 1:1 ratio. Random-
isation will occur immediately following baseline data
collection and participants will be informed by the lay
Fig. 2 Trial Flow diagram
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advisor of their allocation. A computerised random
number sequence will be generated to indicate group
allocation. This will be facilitated through a bespoke
database. Lay advisors will be blind to the randomisa-
tion sequence in order to minimise any selection bias
during recruitment and data collection. Only the dir-
ect trial team will have access to this information for
back-up randomisation purposes.
Data collection
Table 2 provides a breakdown of data collection across
time points. A data management plan will outline how
all data will be collected, managed and stored. All data
will be managed in strict confidence according to GDPR
(EU 2016/679).
Participants will complete the adapted ABC questionnaire
at baseline, 2 weeks and 6months post-randomisation. Base-
line data will be collected electronically via an IPad and en-
tered directly onto the bespoke trial database. Follow-up data
will primarily be collection on the phone and inputted dir-
ectly on the database, however if participants cannot be
contacted after four attempts, paper case report forms will
be sent via the post.
To support the process evaluation, a purposive sample
(based on setting type, age and gender) of participants
will be interviewed at 2–6 weeks post intervention deliv-
ery (n = 30) and post-trial (n = 15–20). A purposive sam-
ple (based on setting type, age and gender) of health
check sessions (20%, n = 24/123) will be audio-recorded
and half of these (10%, n = 12/123) will be purposive
sampled (based on setting type, age and gender) to be
additionally observed. Lay advisors will be interviewed
before beginning participant recruitment and at the end
of recruitment (n = 3 + 3). Site summary logs will be
completed for each recruitment day to record further
process data.
Incentives
As a thank you for their time, participants will be offered
high street shopping vouchers to the value of £15. They
will receive a £10 voucher after completing the baseline
questionnaire and a £5 voucher after completing the
Table 2 Enrolment/Assessments schedule [42]
Procedures/Time point Set-up Screening Baseline Intervention Follow-up
- 1 month B (over 12 months) + 2 weeks + 6 months
Recruitment
Eligibility assessment X
Informed consent X
Contact details form X
Randomisation X
Data collection
Demographic questionnaire X
Medical history questionnaire X
Adapted ABC measure X X X
Cancer worry X X X
Lifestyle questionnaire X X X
Resource use X X
Intervention Delivery
Lay advisor training X
Intervention delivery or control X
Process measures
Interviews with HCAs X X
Site summary logs X
Lay advisor timesheets X X X
Observation/Audio recording of
Intervention delivery
X
Participant Interviews
(2–6 weeks)
X
Participant exit interviews
(post trial)
X
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6-month questionnaire. A sample of participants will be
offered a further £10 voucher for taking part in an
interview.
Process evaluation
In parallel to the trial, a process evaluation will be con-
ducted following the MRC guidance [31] to assess: fidel-
ity (whether the intervention has been delivered as
intended and as a measure of quality assurance); dose
(whether tailored BCTs were delivered according to par-
ticipant self-reported behaviours during the health
check); contamination (whether there were any external
factors that may have influenced participant behaviour/
responses); reach (whether the target population re-
ceived the intervention); key mechanisms of change
(which components of the intervention may have caused
change i.e. mapped BCTs according to domain questions
e.g. increased symptom recognition as a results of in-
creased capacity (i.e. specific knowledge and BCTs: infor-
mation about health consequences)). The evaluation will
draw on a combination of qualitative (observations and
interviews) and quantitative (recruitment numbers, re-
source use, manual adherence) data.
Fidelity of adherence to the intended intervention
delivery and tailored BCTs dose delivery will be
assessed in the process evaluation. A sample of ses-
sions (20%, n = 24/123) will be audio-recorded and
half of these (n = 12/123) will additionally be ob-
served to ascertain the extent to which the interven-
tion was delivered according to the manual and to
assess the levels of exposure. A structured coding
framework will be developed to support the assess-
ment of fidelity and dose.
Sample size
A sample of 246 participants is required in order to
achieve 90% power to detect an effect size of 0.5 in the
primary outcome of cancer symptom recognition, using
a two-sided test and 5% significance threshold, and as-
suming 30% attrition at two weeks follow-up. An effect
size of this magnitude equates to intervention partici-
pants recognising on average one extra cancer symptom
during the follow-up period (SD = 2.2) [32].
Quantitative Analysis
Adapted ABC questionnaire validation
The baseline data from the adapted ABC questionnaire
will be used to explore properties such as item function-
ing, responsiveness, validity and reliability. Factor ana-
lysis and summary statistics will be used to determine
internal consistency and item correspondence to con-
structs underlying the outcome measures.
Descriptive
Descriptive statistics of demographic variables (age, gen-
der, ethnicity, marital group, access to health care, pres-
ence of comorbid conditions, socioeconomic indicators,
i.e. educational attainment and occupational status) and
outcomes for baseline and follow-up, split by treatment
arm, will be presented to summarise the unadjusted data.
The response rate will be similarly summarised. Assess-
ment of drop-out bias will not be tested but will tabulate
the baseline demographic descriptives of those completing
and those not completing the 2 week follow-up.
Main analyses
The primary analysis will be on a complete case basis
following intention-to-treat principles, and will deter-
mine the difference in ABC score between the two arms
at 2 weeks, including baseline cancer symptom recogni-
tion as a covariate. The distributional assumptions of the
linear model will be checked by visual inspection of fit-
ted versus residuals plots. The primary outcome data
will be transformed where appropriate. If they remain
non-normal, bootstrapping will be used to generate re-
gression coefficients and confidence intervals. The mean
(SD) ABC for the control and intervention groups at
baseline and follow-up will be tabulated. The primary
outcome effect will be reported unadjusted and adjusted
for baseline ABC, with 95% CI and p-value. Covariates
to be considered for inclusion in the model are age, gen-
der, recruitment setting and socio-economic group (as
measured by area level deprivation using the IMD [23]
and WIMD [24]. Secondary outcomes will be analysed
similarly. Proposed sensitivity analyses include the investi-
gation of missing data and the use of multiple imputation
for the primary outcome. We will also investigate the ef-
fect of collection time of the primary outcome (within/
without the specified time window). Pre-specified interac-
tions of interest are age and gender with the intervention.
A detailed Statistical Analysis Plan (SAP) will be com-
pleted and signed off before the database is locked and
analysis begins. The trial statistician will be blind to par-
ticipant allocation during analysis. Study results will be re-
ported in line with the CONSORT statement [33].
The intervention will be delivered by three health check
advisors. Any clustering by advisor in the intervention
arm will be investigated via a partial cluster model of the
primary outcome [34, 35]. The adjusted effect for cluster-
ing (by advisor) with 95% CI, p-value and Intra-Cluster
Correlation will be reported. If the distributional assump-
tions for linearity are not met this analysis will use the bin-
ary primary outcome and generalized modelling.
Qualitative Analysis
Qualitative data (observations, session recordings, par-
ticipant interviews and lay advisor interviews) will be
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transcribed and anonymised for analysis. Thematic and
content analysis will be used. Where possible, data will
be triangulated and evidence derived from the process
evaluation will be used to inform which aspects of the
health check might make a change in relation to the out-
comes. Details of the analysis to be conducted are out-
lined below. A Qualitative data collection and Analysis
Plan (QAP) will be developed and signed off in advance
of data collection and will be regularly reviewed during
data collection and analysis.
Observations of health check sessions
Observations/audio recordings will be analysed for two
main purposes. Firstly, we will ascertain fidelity by con-
tent coding anonymised transcripts of health check ses-
sions for evidence of the BCTs identified in the health
check manual [19, 36]. A fidelity definition and accept-
able range will be agreed upon by the team in advance.
Two researchers will be involved in coding transcripts
independently and a subset will be double-coded to as-
sess inter-rater reliability. Fidelity will be assessed using
content analysis by:
(a) comparing manual-specified BCTs with the number
of BCTs delivered in health check sessions;
(b) comparing delivery of BCTs according to session
duration, advisor and site;
(c) examining discrepancies between health check
advisors’ self-reported coverage and actual coverage
of BCTs, and delivery of any BCTs that are not stip-
ulated in the health check manual.
Secondly, we will carry out further inductive thematic
analysis [37] of the audio-recorded health check sessions
to gain a deeper understanding of social context and con-
structions of cancer awareness and help-seeking. Dual
coding will be undertaken to reduce potential bias [37].
Interviews
Anonymised participant interview transcripts and lay ad-
visor paired interviews will be analysed thematically [37],
with 20% double coded (to ensure consistent under-
standing of code definitions and application between
coders), to explore which aspects of the health check
were perceived to be most useful, why and participants’
potential experiences of wider contextual contamination
(i.e. other cancer awareness campaigns).
Health Economic Analysis
The trial will include a health economic evaluation from
an NHS perspective to provide an estimation of costs
and cost-effectiveness of the health check intervention.
No discounting will be applied as the length of interven-
tion and follow-up do not exceed one year.
Implementation cost of the intervention will be calcu-
lated from resource use and standard unit costs (where
available) as well as financial records. Resource use asso-
ciated with the intervention will be established from site
summary forms and through interviews with the lay ad-
visors. The main components are expected to be lay ad-
visor training, supervision and support, and advisor time
and travel. As the intervention will be provided in rou-
tine health care and non-medical community support
settings, we do not anticipate additional costs to the par-
ticipants and will therefore not collect out-of-pocket ex-
penses as part of the implementation cost. Healthcare
resource use will be measured using an adapted Client
Service Receipt Inventory to compare differences at
baseline and six months.
The implementation cost will be compared to the out-
comes of the trial in tabular form as part of a
cost-consequences analysis that will allow comparison of
costs to the main trial outcomes. We do not expect any
short-term effect of the intervention on participants’
quality-of-life and will not collect these data as part of
the health economic analysis. Cost-effectiveness analyses
will be conducted for clinical outcomes where statisti-
cally significant differences were found. These analyses
will calculate the cost per point improvement (e.g. in
cancer symptom awareness, anxiety etc.) and present the
results as incremental cost-effectiveness ratios. Uncer-
tainty will be assessed using one-way deterministic and
probabilistic sensitivity analyses with key parameters var-
ied within plausible ranges (e.g. 95% CIs) and
cost-effectiveness acceptability curves will be presented.
If feasible, we will develop a simple decision-analytic
model to extrapolate costs and outcomes to a
longer-term horizon using the intervention costs and
trial outcomes. These will be supported by data available
in the published literature reporting health outcomes in
relation to cancer symptom awareness. Feasibility of the
modelling exercise will depend on data availability in the
public domain and the trial outcomes. If the trial were
not to find any significant differences in the primary or
secondary outcomes, modelling will be considered
non-feasible. A review of the relevant literature will be
conducted to inform the model. Deterministic and (if
feasible) probabilistic sensitivity analyses will be con-
ducted to account for the uncertainty in key parameters
informing the analysis.
Ethics
This trial has been assessed as low risk. No adverse
events are being collected due to the short contact
period with each participant and the potential for this to
create unnecessary burden on participants. Informed
consent is taken from each participant at recruitment.
Where a participant has not consented to take part in a
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qualitative interview, intervention delivery audio record-
ing or observation they will not be approached regarding
these aspects of the trial.
Some participants may find it difficult to talk about
cancer, may find questions about cancer symptoms un-
comfortable to discuss or may feel embarrassed about
their lifestyle. When dealing with participants, re-
searchers will be mindful that questions could be upset-
ting and that the social determinants of health, including
the person’s environment, are important drivers of be-
haviour [38] alongside self and societal stigma relating to
obesity, smoking and alcohol use [39, 40].
Research staff are experienced in collecting sensitive
data and specific training is provided to support staff. In
order to provide participants with privacy to discuss
their responses with the lay advisor, the baseline assess-
ments take place in a private room. Participants are
reminded that their participation is highly confidential
and any information they share will not be shared with
other parties. Follow-up phone assessments are sched-
uled at a time suitable to participants which allows them
to find a private space to talk. However, if at any point
any participant becomes upset they are provided with
support and, where appropriate, additional support ser-
vices are highlighted to them. Participants are addition-
ally offered a break and/or are able to continue their
participation at a different date/time if they wish.
Research data will be held for 15 years and archived
securely. This is in line with Cardiff University policies.
Dissemination
Study results will be disseminated widely through aca-
demic, clinical, policy and community networks and to
trial participants. An inclusive publication policy has
been developed to support this and provides all mem-
bers of the team with an opportunity to volunteer ideas
and input to planned outputs. The publication policy
will be discussed at monthly meetings and any new ideas
added.
Disscussion
This is the first randomised controlled trial of a facili-
tated behaviour change intervention aimed at improving
cancer awareness in socioeconomically deprived com-
munities in the UK. Previous research suggests that tai-
lored community-based interventions delivered by
trusted lay advisors could lead to an increase in cancer
symptom awareness and encourage help-seeking behav-
iour among adults living in disadvantaged communities,
for whom long-term health may not be a priority due to
competing life demands and low socioeconomic re-
sources [39]. High quality evidence is needed to test the
effectiveness of such interventions within real life set-
tings. The current trial follows on from theory modelling
[19] and feasibility testing [16], according to the MRC
guidance on developing and evaluating complex inter-
ventions [22]. We aim to reach individuals in deprived
areas who experience the poorest long-term cancer out-
comes. However, despite broad inclusion criteria, the
trial excludes individuals who lack capacity to provide
informed consent and those who do not speak English,
who may have the highest need. In addition, it is not de-
signed to reach members of the community who do not
or who are unable to (e.g. people who are housebound)
attend the community venues that are targeted within
this trial. Arguably, these populations may have higher
needs and may be even harder to reach and engage [41].
Future research could consider how to extend reach to
these populations within disadvantaged communities.
Conclusion
The findings of the trial will be critical to informing effect-
ive methods of engaging high risk disadvantaged popula-
tions in cancer awareness, with the potential to reduce
socioeconomic inequalities in cancer outcomes and the
possibility of wider implementation across the UK.
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